TROD Medical

About:

TROD Medical is focused on the development of radio frequency ablation technologies.

Website: http://trodmedical.com

Top Investors: PMV, Capricorn Partners, Vesalius Biocapital Partners, Gemma Frisius Fund

Description:

Trod Medical is a Medical Device Company, with headquarters in Leuven (Belgium) and Tampa Bay area (USA). The Company, incepted in 2006 by Dr. Andre Faure, developed significant expertise in developing innovative ablation technologies, particularly Radio Frequency (RF) ablation devices. Trod Medical developed a disruptive percutaneous RF device, the EncageTM, able to ablate tissues with a degree of precision unmatched by competition. The technology represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, like prostate cancer. Prostate Cancer is one of the most common cancers, with around 240,000 new cases per year in the US alone, and is notably known for the inability of its commonly used treatments in avoiding significant side effects, like erectile dysfunction (impotence) and urinary incontinence.

Total Funding Amount:

4.75M EUR

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Paris, Ile-de-France, France

Founded Date:

2006-01-01

Contact Email:

info(AT)trodmedical.com

Founders:

Andre Faure

Number of Employees:

11-50

Last Funding Date:

2013-10-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai